Is nitric oxide (NO) the last word in radiosensitization? A review

Translational Oncology

Volumn 5, Issue 2, 2012, Pages 66-71

  Oronsky, Bryan T ^a   Knox, Susan J ^b   Scicinski, Jan J ^a  

^a RadioRx Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; CD47 ANTIGEN; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; OXYGEN; THROMBOSPONDIN 1;

ARTICLE; BLOOD RHEOLOGY; ERYTHROCYTE; HUMAN; HYPOXIA; MITOCHONDRIAL RESPIRATION; RADIATION INJURY; RADIATION PROTECTION; RADIOSENSITIZATION; TUMOR MICROENVIRONMENT; VASODILATATION;

EID: 84859462316     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11307     Document Type: Article

References (48)

1. Feelisch M and Martin JF (1995). The early role of nitric oxide in evolution. Trends Ecol Evol 10, 496-499.
2. Sarti P, Avigliano L, Gorlach A, and Brune B (2002). Superoxide and nitric oxide-participation in cell communication. Cell Death Differ 9, 1160-1162.
3. Gow AJ (2006). The biological chemistry of nitric oxide as it pertains to the extrapulmonary effects of inhaled nitric oxide. Proc Am Thorac Soc 3, 150-152.
4. Brennan PA, Conroy B, and Spedding AV (2000). Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90, 624-629.
5. Beckman JS and Koppenol WH(1996). Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271, C1424-C1437.
6. Wang J, Torbenson M, Wang Q, Ro JY, and Becich M (2003). Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 21, 117-122.
7. Jadeski LC, Hum KO, Chakraborty C, and Lala PK (2000). Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 86, 30-39.
8. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, and Hoskin PJ (2007). Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118.
9. Worthington J, Robson T, O'Keeffe M, and Hirst DG (2002). Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther 9, 263-269.
10. Heaton JP, Adams MA, Graham CH, Emerson L, and Siemens RD (2003). Evidence for the use of low dose nitric oxide in the treatment of rising PSA associated with biochemical failure following radical prostatectomy. J Urol 169(Suppl. S), 1082.
11. Wang C, Trudel LJ, Wogan GN, and Deen WM (2003). Thresholds of nitric oxide-mediated toxicity in human lymphoblastoid cells. Chem Res Toxicol 16, 1004-1013.
12. Oronsky BT, Knox SJ, and Scicinski J (2011). Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol 4, 189-198.
13. De Ridder M, Verellen D, Verovski V, and Storme G (2008). Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 19, 164-169.
14. Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR, and Blumberg D (2004). Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64, 8015-8021.
15. Jordan BF, Sonveaux P, Feron O, Gregoire V, Beghein N, Dessy C, and Gallez B (2004). Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer 109, 768-773.
16. Ducrocq C, Blanchard B, Pignatelli B, and Ohshima H (1999). Peroxynitrite: an endogenous oxidizing and nitrating agent. Cell Mol Life Sci 55, 1068-1077.
17. Szabo C, Ischiropoulos H, and Radi R (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6, 662-680.
18. Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, and Yorek MA (2005). Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54, 3435-3441.
19. -). Proc Natl Acad Sci USA 97, 10307-10312.
20. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, and Gallez B (2000). Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48, 565-570.
21. Trotter MJ, Chaplin DJ, and Olive PL (1991). Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur J Cancer 27, 887-893.
22. Agvald P, Adding LC, Gustafsson LE, and Persson MG (1999). Nitric oxide generation, tachyphylaxis and cross-tachyphylaxis from nitrovasodilators in vivo. Eur J Pharmacol 385, 137-145.
23. Hobbs AJ (2002). Soluble guanylate cyclase: an old therapeutic target re-visited. Br J Pharmacol 136, 637-640.
24. Fukumura D and Jain RK (1998). Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 17, 77-89.
25. Bonaventura J (2007). Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc Natl Acad Sci USA 104, 19165-19166.
26. Janssen HL, Haustermans KM, Sprong D, Blommestijn G, Hofland I, Hoebers FJ, Blijweert E, Raleigh JA, Semenza GL, Varia MA, et al. (2002). HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54, 1537-1549.
27. Sonveaux P, Lobysheva II, Feron O, and McMahon TJ (2007). Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) 22, 97-112.
28. Gladwin MT and Schechter AN (2004). NO contest: nitrite versus S-nitrosohemoglobin. Circ Res 94, 851-855.
29. Sonveaux P, Jordan BF, Gallez B, and Feron O (2009). Nitric oxide delivery to cancer: why and how? Eur J Cancer 45, 1352-1369.
30. Jiang H, De Ridder M, Verovski VN, Sonveaux P, Jordan BF, Law K, Monsaert C, Van den Berge DL, Verellen D, Feron O, et al. (2010). Activated macrophages as a novel determinant of tumor cell radioresponse: the role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing. Int J Radiat Oncol Biol Phys 76, 1520-1527.
31. Hagen T, Taylor CT, Lam F, and Moncada S (2003). Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302, 1975-1978.
32. 2 homeostasis. Curr Opin Genet Dev 8, 588-594.
33. Brown GC (2007). Nitric oxide and mitochondria. Front Biosci 12, 1024-1033.
34. Liebmann J, DeLuca AM, Coffin D, Keefer LK, Venzon D, Wink DA, and Mitchell JB (1994). In vivo radiation protection by nitric oxide modulation. Cancer Res 54, 3365-3368.
35. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, Wink DA, Isenberg JS, and Roberts DD (2009). Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 1, 3ra7.
36. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, and Freeman BA (1994). Nitric oxide regulation of superoxide and peroxynitritedependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269, 26066-26075.
37. Howard-Flanders P (1957). Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180, 1191-1192.
38. Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, and Krishna MC (1993). Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53, 5845-5848.
39. Jordan BF, Beghein N, Aubry M, Gregoire V, and Gallez B (2003). Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer 103, 138-141.
40. Thews O, Kelleher DK, and Vaupel P (2001). No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs. Int J Oncol 19, 1243-1247.
41. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, and Dewhirst MW (1997). Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76, 429-437.
42. Janssens MY, Verovski VN, Van den Berge DL, Monsaert C, and Storme GA (1999). Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br J Cancer 79, 1085-1089.
43. Park YK, Ahn DR, Oh M, Lee T, Yang EG, Son M, and Park H (2008). Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxiainducible factor-1α by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation. Mol Pharmacol 74, 236-245.
44. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, and Knox S (2011). Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. In Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, Florida. American Association for Cancer Research, Philadelphia, PA, Abstract no. 676.
45. Isenberg JS, Martin-Manso G, Maxhimer JB, and Roberts DD (2009). Regulation of nitric oxide signalling by thrombospondin 1: implications for antiangiogenic therapies. Nat Rev Cancer 9, 182-194.
46. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, and Roberts DD (2007). Increasing survival of ischemic tissue by targeting CD47. Circ Res 100, 712-720.
47. Wardman P (2007). Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19, 397-417.
48. de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, Ellard S, Gordon RJ, Brindley CJ, and Evans TR (2000). Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6, 397-405.